British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK is one of the few that continues to invest in the area. The British pharma touts one of the “largest and most diverse” infectious disease pipeline in the industry. Still, it’s a ...

Bearish flow noted in GSK (GSK) Pharma with 6,103 puts trading, or 5x expected. Most active are 3/14 weekly 39.5 puts and Mar-25 41.5 calls, with total volume in those strikes near 5,500 contracts.

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are creating turbulence within the Pharma sector.

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer.

Associate Global Pharmaceutical Analyst at GlobalData. She added that GSK may be getting more bang per buck in terms of its R&D investment, with seven drugs in pre-registration phase compared with ...

GSK Pharma Q3 results 2025: GlaxoSmithKline Pharma Ltd announced its Q3 results today posting a solid jump in its net profit. Consolidated PAT for the quarter surged by a robust 402 per cent.

GSK) stands against the other most undervalued biotech stocks to invest in. Trump’s Tariffs and the Pharma Sector On February 21, Jared Holz, Mizuho Securities America’s healthcare sector ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...